|
US3654349A
(en)
|
1970-05-01 |
1972-04-04 |
Merck & Co Inc |
Substituted indenyl acetic acids
|
|
US3647858A
(en)
|
1970-05-01 |
1972-03-07 |
Merck & Co Inc |
Process for preparing 1-benzylidene-3-indenyl acetic acids
|
|
US4309442A
(en)
|
1977-07-11 |
1982-01-05 |
Merrell Toraude Et Compagnie |
Method for controlling fertility in mammals
|
|
US4330559A
(en)
|
1977-07-11 |
1982-05-18 |
Merrell-Toraude Et Cie |
Method of treating benign prostatic hypertrophy
|
|
US4413141A
(en)
|
1977-07-11 |
1983-11-01 |
Merrell Toraude Et Compagnie |
2-(Difluoromethyl)-2,5-diaminopentanoic acid
|
|
US4499072A
(en)
|
1982-11-29 |
1985-02-12 |
Merrell Dow Pharmaceuticals Inc. |
Process for treating diseases with ODC inhibitors
|
|
US4859452A
(en)
|
1986-01-17 |
1989-08-22 |
Board Of Regents, The University Of Texas System |
Methods for the reduction of difluoromethylornithine associated toxicity
|
|
US4925835A
(en)
|
1986-05-01 |
1990-05-15 |
Sloan-Kettering Institute For Cancer Research |
Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
|
|
US5002879A
(en)
|
1986-05-06 |
1991-03-26 |
Merrell Dow Pharmaceuticals |
Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
FR2706255B1
(fr)
|
1993-06-17 |
1995-10-27 |
Univ Rennes |
Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
|
|
EP0665852A1
(en)
|
1993-07-09 |
1995-08-09 |
Amgen Boulder Inc. |
Recombinant ctla4 polypeptides and methods for making the same
|
|
US5456908A
(en)
|
1994-03-01 |
1995-10-10 |
The University Of Kentucky Research Foundation |
Polyamine-polyamine and polyamine-protein transport inhibitor conjugates and their use as pharmaceuticals and in research relating to polyamine transport
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
US5843929A
(en)
|
1996-03-22 |
1998-12-01 |
Mayo Foundation For Medical Education And Research |
Chemoprevention of metachronous adenomatous colorectal polyps
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US6083496A
(en)
|
1996-10-22 |
2000-07-04 |
Universite Laval |
Polyamine transport inhibitors
|
|
CA2241896A1
(en)
|
1996-11-01 |
1998-05-14 |
Ze'ev Shaked |
Sustained release formulation containing dfmo
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
CA2325080A1
(en)
|
1998-03-28 |
1999-10-07 |
The Regents Of The University Of California |
Dfmo and sulindac combination in cancer chemoprevention
|
|
AU7131698A
(en)
|
1998-04-21 |
1999-11-08 |
Ilex Oncology, Inc. |
Polyamine transport inhibitors
|
|
US7700568B2
(en)
|
1998-06-30 |
2010-04-20 |
Sloan-Kettering Institute For Cancer Research |
Uses of DNA-PK
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
US6753422B2
(en)
|
1999-03-01 |
2004-06-22 |
O'brien Thomas G. |
Odc allelic analysis method for assessing carcinogenic susceptibility
|
|
CA2373931A1
(en)
|
1999-05-17 |
2000-11-23 |
Richard Love |
Dfmo and celecoxib in combination for cancer chemoprevention and therapy
|
|
US6428809B1
(en)
|
1999-08-18 |
2002-08-06 |
Microdose Technologies, Inc. |
Metering and packaging of controlled release medication
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US6602910B2
(en)
|
2000-03-07 |
2003-08-05 |
Ilex Oncology, Inc. |
D-enantiomer of DFMO and methods of use therefor
|
|
WO2001068076A2
(en)
|
2000-03-07 |
2001-09-20 |
Ilex Oncology, Inc. |
D-enantiomer of dfmo and methods of use thereof for treating cancer
|
|
EP1351675A2
(en)
|
2000-08-24 |
2003-10-15 |
The Regents of the University of California |
Alpha-difluoromethylornithine (dfmo) use in the human prostate
|
|
JP2005510524A
(ja)
|
2001-11-16 |
2005-04-21 |
アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド |
ポリアミン経路の調節による神経変性障害の治療
|
|
EP1575584A4
(en)
|
2002-11-29 |
2006-02-01 |
Forest Laboratories |
METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
|
|
US20100009929A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
US9072778B2
(en)
|
2005-12-20 |
2015-07-07 |
University Of Hawaii |
Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
|
|
BRPI0714937A2
(pt)
|
2006-07-18 |
2013-03-26 |
Horizon Therapeutics, Inc. |
forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria
|
|
HUE029445T2
(en)
*
|
2006-12-19 |
2017-02-28 |
Genentech Inc |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2009015981A2
(en)
|
2007-08-01 |
2009-02-05 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Treatment of pediatric tumors
|
|
US8283331B2
(en)
|
2007-10-09 |
2012-10-09 |
Children's Medical Center Corporation |
Methods to regulate miRNA processing by targeting Lin-28
|
|
CN101970499B
(zh)
|
2008-02-11 |
2014-12-31 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
CN102164962B
(zh)
|
2008-06-30 |
2014-05-28 |
诺福泰克公司 |
抗gd2抗体和方法及其相关应用
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
KR20110073500A
(ko)
|
2008-09-08 |
2011-06-29 |
메르크 파텐트 게엠베하 |
오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
|
|
US20100120727A1
(en)
*
|
2008-11-12 |
2010-05-13 |
Kyphia Pharmaceuticals, Inc. |
Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
|
|
EP2355775B1
(en)
|
2008-12-08 |
2017-06-21 |
The Procter and Gamble Company |
Personal care composition in the form of an article having a hydrophobic surface-resident coating
|
|
PT2430452E
(pt)
|
2009-05-14 |
2014-09-30 |
Univ Arizona State |
Diagnóstico e tratamentos de carcinoma com base no genótipo odc1
|
|
WO2010134047A2
(en)
|
2009-05-20 |
2010-11-25 |
Ranbaxy Laboratories Limited |
Liquid dosage forms of isotretinoin
|
|
WO2010148390A2
(en)
|
2009-06-19 |
2010-12-23 |
University Of Central Florida Research Foundation, Inc. |
Polyamine transport inhibitors as novel therapeutics
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
HUE030100T2
(en)
|
2010-02-19 |
2017-04-28 |
Xencor Inc |
New CTLA4-IG immunoadhesins
|
|
US20110256161A1
(en)
|
2010-04-19 |
2011-10-20 |
Aminex Therapeutics Inc. |
Methods for enhancing immune response
|
|
CA2800557A1
(en)
|
2010-04-29 |
2011-11-03 |
Medical Prognosis Institute A/S |
Methods and devices for predicting treatment efficacy
|
|
CA2799431A1
(en)
|
2010-05-14 |
2011-11-17 |
Cancer Prevention Pharmaceuticals, Inc. |
Cancer prevention and treatment methods based on dietary polyamine content
|
|
EP3323830B1
(en)
|
2010-06-19 |
2023-08-23 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
|
WO2012033885A1
(en)
|
2010-09-08 |
2012-03-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered gd2-specific t cells
|
|
WO2012135641A2
(en)
|
2011-03-30 |
2012-10-04 |
H. Lee Moffitt Cancer Center And Research Institute |
Aurora kinase inhibitors and methods of making and using thereof
|
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
HUE040263T2
(hu)
|
2012-10-29 |
2019-02-28 |
Arizona Board Of Regents On Behalf Of Univ Of Arizona |
Prediktív markerek poliamin-inhibitor rákterápiákhoz
|
|
GB2513299A
(en)
|
2013-03-12 |
2014-10-29 |
Cellact Pharma Gmbh Biomedizinzentrum |
Compounds for targeting cancer stem cells
|
|
RU2680267C2
(ru)
|
2013-03-15 |
2019-02-19 |
Мемориал Слоан Кеттеринг Кэнсер Сентер |
Высокоаффинные антитела к gd2
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
AU2014296887A1
(en)
|
2013-08-02 |
2016-01-28 |
Aduro Biotech Holdings, Europe B.V. |
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
WO2015195120A1
(en)
|
2014-06-18 |
2015-12-23 |
Arizona Board Of Regents On Behalf Of University Of Arizona |
Carcinoma diagnosis and treatment based on odc1 genotype
|
|
CA2976106A1
(en)
*
|
2015-02-12 |
2016-08-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods for treating neuroblastoma
|
|
MA43114A
(fr)
*
|
2015-10-30 |
2018-09-05 |
Cancer Prevention Pharmaceuticals Inc |
Formulation combinée à dose fixe d'éflornithine et sulindac
|
|
WO2017075576A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Cancer Prevention Pharmaceuticals, Inc. |
Eflornithine and sulindac, fixed dose combination formulation
|
|
CN114096240A
(zh)
*
|
2019-05-17 |
2022-02-25 |
癌症预防制药股份有限公司 |
用于治疗家族性腺瘤性息肉病的方法
|